DR AGARWALS HEALTH CARE L (AGARWALEYE.NS)
- Previous Close
364.90 - Open
363.05 - Bid --
- Ask --
- Day's Range
351.00 - 368.45 - 52 Week Range
351.00 - 464.00 - Volume
471,299 - Avg. Volume
1,111,482 - Market Cap (intraday)
111.752B - Beta (5Y Monthly) --
- PE Ratio (TTM)
127.65 - EPS (TTM)
2.77 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
474.25
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contact lens. The company also provides surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty, and surgeries for the treatment of glaucoma and pterygium; doctor consultation services; and diagnostic services for eye disorders along with non-surgical treatments, including retinal laser therapy and dry eye treatment services. It also sells glasses, lenses, contact lenses, and frames; and eye care-related pharmaceutical products. The company was incorporated in 2010 and is based in Chennai, India.
www.dragarwals.co.inRecent News: AGARWALEYE.NS
View MorePerformance Overview: AGARWALEYE.NS
Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AGARWALEYE.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AGARWALEYE.NS
View MoreValuation Measures
Market Cap
112.13B
Enterprise Value
117.57B
Trailing P/E
128.62
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.48
Price/Book (mrq)
7.45
Enterprise Value/Revenue
7.85
Enterprise Value/EBITDA
25.77
Financial Highlights
Profitability and Income Statement
Profit Margin
5.60%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
16B
Net Income Avi to Common (ttm)
896.41M
Diluted EPS (ttm)
2.77
Balance Sheet and Cash Flow
Total Cash (mrq)
4.91B
Total Debt/Equity (mrq)
66.39%
Levered Free Cash Flow (ttm)
--